Crinetics Shares Nearly Double After Vertex Agrees $10 Billion Cash Buyout
2026-07-08 03:20:15
Crinetics Pharmaceuticals shares nearly doubled on Monday, July 6 after Vertex Pharmaceuticals agreed to buy the company for $10 billion in cash. According to BeInCrypto, Vertex will pay $85 a share, roughly double Crinetics’ prior close. Crinetics makes Palsonify, a once-daily pill for acromegaly, and has a second late-stage drug for another rare hormone condition; the two products could generate more than $5 billion a year at peak sales. William Blair analyst Myles Minter said the price is reasonable if that target is met. The deal is expected to close in the third quarter.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
